COVID-19 Vaccine EUA Process Compresses Advisory Committee Prep Too

US FDA wants briefing documents when EUA is submitted to accommodate timely advisory committee reviews; unlike traditional assessment process, the agency does not appear interested in engaging in back-and-forth discussions with sponsors about portions of the briefing document that should be made public or redacted.

MT2007_FDA Advisory Comm_292512269_1200.jpg
Sponsors must include advisory committee presenter slides, as well as meeting briefing materials, with their coronavirus vaccine EUA request. • Source: Shutterstock

The US Food and Drug Administration expects coronavirus vaccine sponsors to begin preparing for an advisory committee meeting before their emergency use authorization request is even filed in order to comply with compressed assessment timelines.

New guidance indicates that sponsors should include “briefing materials summarizing data to support the safety and effectiveness of the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers